Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Slides:



Advertisements
Similar presentations
I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.
Advertisements

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S.
Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.
T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
CLINICAL OUTCOME OF 251 PATIENTS WITH EXTRAHEPATIC METASTASIS AT INITIAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: DOES TRANSARTERIAL CHEMOEMBOLIZATION IMPROVE.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
SCTS Education day “Radiotherapy in 2016”
Brain imaging prior to lung cancer resection
Perioperative Complications after Neoadjuvant Chemoradiation for Locally-Advanced Esophageal Cancer: A Comparison of Platinum/5-FU and Carboplatin/Paclitaxel.
Su K. Metcalfe, MD, MPH, Michael T
Comparative Toxicity Profiles of Two Platinum Doublets: Real Life Experience from a Cancer Unit Jessop S, Jeffs Y P, Thomas E, Azher M, Adu Poku K, Sa'D.
Prognostic Implications of Neutrophil to Lymphocyte Ratio in the Treatment of Metastatic Renal Cell Carcinoma with Pazopanib and Sunitinib Ajay Raghunath1,
Mesothelioma studies within our region – 2016 update Nick Maskell
TEXILA AMERICAN UNIVERSITY
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Volume 383, Issue 9928, Pages (May 2014)
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.
Compassionate People World Class Care
Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Director Department of Pediatric Hematology & Oncology Delhi, INDIA.
Curative treatment rates for patients diagnosed with
National Resource Center for Late Effects after Cancer Treatment
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
Prognosis of younger patients in non-small cell lung cancer
930P - A retrospective single institution study evaluating clinical outcome and prognostic markers for endometrial and ovarian carcinosarcomas (CS) U.Asghar1,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Table 1 Baseline patient characteristics
Intervista a Lucio Crinò
Intervista a Angelo Delmonte
Stereotactic ablative radiotherapy (SABR) versus lobectomy for operable stage I NSCLC Julia Myers.
National Lung Cancer Audit
New developments in oncological treatment for Stage 3 NSCLC
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,
ACT II: The Second UK Phase III Anal Cancer Trial
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Published online September 20, 2017 by JAMA Surgery
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.
Volume 9, Issue 4, Pages (April 2008)
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Volume 383, Issue 9928, Pages (May 2014)
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.
NAACCR/IACR Combined Annual Conference 2019
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.
Prognosis of angiosarcoma at different anatomic sites
Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Results: Purpose/Objectives: Methods: Conclusions:
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-
Volume 20, Issue 8, Pages (August 2019)
Presentation transcript:

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients Robinson SD, Absalom KAR, Das T, Lee C, Fisher PM, Bates E, Hatton MQ Department of Clinical Oncology, Weston Park Hospital, Sheffield Background: Radical radiotherapy (RT) regimens for NSCLC vary considerably and there is little data on outcomes for elderly patients who are underrepresented in clinical trials. In routine practice our centre has used continuous hyperfractionated accelerated radiotherapy (CHART, 54Gy in 36 fractions, Figure 1) and accelerated hypofractionated RT (55 Gy in 20 fractions, Figure 2) since 1997. We have audited outcomes for patients over the age of 80 treated between 2005 – 2011. Results - Demographics and Treatment: Of the 516 patients received radical radiotherapy 73 were over 80 years old with 71% being male and 85% WHO performance status 0-1. PET staging was performed in 87% with 41%, 22% and 32% being stage 1, 2, 3 respectively. 51% were squamous carcinomas, 18% non-squamous, 12% NOS with 19% without a confirmed histological diagnosis. 2 patients received primary chemotherapy, with 40% receiving CHART and 56% hypofractionated RT (Figure 3). All completed their prescribed radiotherapy treatment. Results - Survival: 2 year survival was 67% and median overall survival (OS) from time of diagnosis was 22 months. Univariate subgroup analysis showed stage as the only statistically significant variables affecting survival (Figure 4). Figure 4. Kaplan-Meier plot of Overall Survival and significance levels from a univariate analysis for individual variables p Value Gender 0.468 PS 0.685 Histology 0.218 Stage 0.005 PET 0.669 Regime 0.518 Age 0.271 Figure 3. Pie charts representing proportions of patients in each sub-group Discussion: This audit has confirmed accelerated radiotherapy schedules are deliverable to the elderly population with NSCLC who were generally not considered suitable for standard treatment with chemo-radiotherapy. The outcomes are similar to those reported in our younger patient cohorts [1] and appear to be as good as those reported in the original CHART paper [2]. Materials and methods Case notes and radiotherapy records for all patients receiving radical radiotherapy were retrospectively reviewed. Basic patient demographics, tumour characteristics, RT and survival data were collected. Descriptive statistical analysis and Cox regression analysis was performed using SSPS. Conclusions: The use of accelerated radiotherapy fractionations for the radical treatment of elderly patients with NSCLC is a feasible and well tolerated treatment for those patients not suitable for a chemo-radiotherapy approach. Outcomes are encouraging but trials specific to this population are needed to define the best radiotherapy fractionations in this elderly population. References: 1.Pemberton LS, Din OS, Fisher PM, Hatton MQ. Accelerated radical radiotherapy for non-small cell lung cancer (NSCLC) using two common regimens: a single centre audit of outcome. Clinical Oncology 2009;21:161-7 2. Saunders M et.al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997 Jul 19;350(9072):161-5